Abstract:Abstract Background Mirikizumab, a p19-directed interleukin-23 monoclonal antibody, is efficacious in inducing clinical remission at week 12 (W12) and maintaining clinical remission at W52 in patients with moderately to severely active ulcerative colitis. Results are presented from the open-label extension study through W104. Methods Clinical, symptomatic, quality-of-life, and adverse event outcomes are reported for mirikizumab induction responders and extended induction responders, including biologic-failed patients, who entered LUCENT-3, with data shown for W52 maintenance responders or remitters. Discontinuations or missing data were handled by nonresponder imputation (NRI), modified NRI (mNRI), and observed case (OC). Results Among W52 mirikizumab responders, clinical response at W104 was 74.5%, 87.2%, and 96.7% and clinical remission was 76.6%, 89.0%, and 98.3% for NRI, mNRI, and OC, respectively. Among W52 mirikizumab remitters, clinical response at W104 was 54.0%, 62.8%, and 70.1% and clinical remission was 65.6%, 76.1%, and 84.2%. Using mNRI, remission rates at W104 for W52 clinical remitters were 74.7% corticosteroid-free, 79.5% endoscopic, 63.9% histologic-endoscopic mucosal remission, 85.9% symptomatic, 59.8% bowel urgency, 80.5% Inflammatory Bowel Disease Questionnaire (using NRI), 71.2% histologic-endoscopic mucosal improvement, and 77.5% bowel urgency improvement. Previous biologic-failed vs not-biologic-failed patient data were generally similar. Extended induction mNRI clinical response was 81.9%. Serious adverse events were reported in 5.2% of patients; 2.8% discontinued treatment due to adverse events. Conclusions Endoscopic, histologic, symptomatic, and quality-of-life outcomes support the long-term benefit of mirikizumab treatment up to 104 weeks in patients with ulcerative colitis, including biologic-failed patients, with no new safety concerns.

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to explore the long - term efficacy and safety of Mirikizumab in treating patients with moderately - to - severely active ulcerative colitis (UC). Specifically, the study focuses on the following issues: 1. **Assessment of long - term efficacy**: - The clinical response and clinical remission rates of Mirikizumab during 104 weeks (two years) of continuous treatment after induction of remission. - In particular, for those patients who were previously unresponsive to biologics, whether Mirikizumab can maintain long - term efficacy. 2. **Multiple outcome measures**: - Improvements in endoscopic, histological, and symptomatic aspects. - Improvement in quality of life, including the improvement in the Inflammatory Bowel Disease Questionnaire (IBDQ) score. - Performance of specific outcome measures such as corticosteroid - free remission, endoscopic remission, and histologic - endoscopic mucosal improvement (HEMI). 3. **Safety assessment**: - How safe is Mirikizumab during up to 104 weeks of treatment? Are there any new safety issues? ### Research background Ulcerative colitis is a recurrent inflammatory disease that seriously affects the quality of life of patients. Although there are currently multiple treatment methods, such as corticosteroids, mesalazine, immunosuppressants, Janus kinase inhibitors, and biologics, there are still unmet treatment needs in patients with moderately - to - severely active UC. In particular, for those patients who are unresponsive to traditional or advanced therapies, there is an urgent need for new effective treatment regimens. Mirikizumab is a monoclonal antibody that specifically blocks the IL - 23 p19 subunit and has been proven to have significant efficacy in patients with moderately - to - severely active UC during the induction and maintenance phases. This study further evaluated the long - term efficacy and safety of Mirikizumab in these patients through the LUCENT - 3 open - label extension study. ### Key findings - **Long - term efficacy**: Among the patients who responded to Mirikizumab at 52 weeks, the clinical response rate at 104 weeks was 74.5% - 96.7%, and the clinical remission rate was 76.6% - 98.3% (according to different methods of handling missing data). - **Improvement in multiple outcome measures**: There were significant improvements in endoscopic, histological, symptomatic, and quality - of - life aspects. - **Safety**: No new safety issues were found. The incidence of serious adverse events was 5.2%, and the proportion of discontinuations due to adverse events was 2.8%. ### Conclusion This study shows that Mirikizumab has a continuous and long - lasting efficacy in patients with moderately - to - severely active UC, especially in those who were previously unresponsive to biologics. In addition, Mirikizumab has a good safety profile with no new safety issues. These results provide important long - term treatment data support for clinicians when prescribing this new biologic.

Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme

P901 Extended induction response over time in patients with moderately-to-severely active Ulcerative Colitis treated with mirikizumab in the LUCENT-1 and -2 trials

Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials

OP14 Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis

P932 Corticosteroid-sparing effect of mirikizumab for the treatment of moderately-to-severely active Ulcerative Colitis: Extended induction subgroup analysis from Phase 3 trial

S1493 The Impact of Mirikizumab Induction, Maintenance, and Long-Term Treatment on Disease Clearance in Patients With Moderately to Severely Active Ulcerative Colitis: Post-Hoc Analysis of LUCENT Trials

OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study

OP12 Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trial

Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52

DOP90 The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab

P046 Real-world data on the treatment with Mirikizumab in a mostly biological-experienced Ulcerative colitis cohort

P1044 Mirikizumab Pharmacokinetics and Exposure-Response in a Phase 2 Study in Patients With Moderately to Severely Active Crohn’s Disease

Mirikizumab regulates genes involved in ulcerative colitis disease activity and anti-TNF resistance: results from a phase 2 study

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.

OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study

S1472 Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 Study

DOP65 Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity

Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis

P1048 Mirikizumab administration experience from Ulcerative Colitis patients: Survey data from the LUCENT clinical program

Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study